Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial released Thursday …
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved…
Mitochondrial control of fuel switching via carnitine biosynthesis
Metabolic adaptation to environmental changes, such as fasting and cold exposure, involves a dynamic shift in fuel utilization from glucose to fatty acid oxidation, a process that relies on carnitine-mediated fatty acid oxidation in mitochondria. While dietary sources of animal origin (e.g., red meat) contribute to the carnitine pool, de novo carnitine synthesis from trimethyllysine […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.
STAT+: Eli Lilly’s obesity pill helped patients maintain weight loss after switch from injections
Eli Lilly’s investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, the company said Thursday, results that could widen the appeal of the pill. In a Phase 3 trial, one cohort of patients had an average starting weight of 113.5 kg. After over […]
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
Key Points These two healthcare stocks are top names to invest in, but they haven’t both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo Nordisk, in contrast, has been facing a lot of adversity and has had to cut its guidance due […]
STAT+: Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow
When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an alternative way to get the treatments: Buy them themselves. In a notice viewed by STAT, HCA said use of the GLP-1 weight loss […]
Beyond Weight Loss: GLP-1s Show Promise in Breast Cancer
A growing body of evidence suggests GLP-1 receptor agonists may improve survival as well as reduce chemotherapy-related toxicities in women with breast cancer. Medscape Medical News
IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms262412163 Authors: María Paz Orozco Valentina Vintimilla Rivadeneira Jose E. Leon-Rojas Parkinson’s disease (PD) is a complex neurodegenerative disorder characterised by progressive motor and non-motor impairment, in which current therapies remain symptomatic […]
Recent articles on GLP-1 receptor agonists have presented as part of secondary analyses an effect,trial-product estimand, that may be unfamiliar.
submitted by /u/Accurate_Cry_8937 [link] [comments]